Agios Pharmaceuticals 配当と自社株買い
配当金 基準チェック /06
Agios Pharmaceuticals配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-0.5%
バイバック利回り
| 総株主利回り | -0.5% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブの更新 • Jun 02
AGIO: Sickle Cell FDA Path And Thalassemia Launch Will Drive Next Phase Upside
Agios Pharmaceuticals' updated analyst price target has shifted slightly lower to $40.88 from $41.13, as analysts factor in the tebapivat setback and refocus their models on mitapivat launch execution and the sickle cell disease regulatory path. Analyst Commentary Recent Street research on Agios Pharmaceuticals highlights a split view, with some analysts focusing on potential value from mitapivat and regulatory milestones, while others concentrate on pipeline setbacks, competitive pressures and addressable market questions.Seeking Alpha • May 29
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
Summary Agios Pharmaceuticals, Inc. is initiated at Sell due to pipeline setbacks and intensifying competition in PK activators. AGIO discontinued tebapivat in LR-MDS after failing a phase 2b threshold, leaving SCD as its primary near-term catalyst. Novo Nordisk's etavopivat has achieved positive phase 3 SCD results and is expected to file for approval in the 2nd half of 2026. Despite $1B in cash, company faces uncertain differentiation and commercial prospects for tebapivat in SCD, with current sales momentum limited in PYRUKYND and AQVESME. Read the full article on Seeking Alphaナラティブの更新 • May 18
AGIO: FDA Sickle Cell Decision And Trial Data Will Shape Next Phase Upside
Analysts have trimmed their consolidated price target for Agios Pharmaceuticals by about $0.40 to roughly $41.10. This reflects updated assumptions on market size, profit margins and future P/E after a mix of recent target cuts and raises across the Street.
ナラティブの更新 • May 01
AGIO: Sickle Cell FDA Path And Novo Readthroughs Will Shape Future Enthusiasm
Analysts have adjusted their outlook on Agios Pharmaceuticals with a modestly lower average price target, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E following recent mixed research, including several target cuts tied to Novo Nordisk related market views and earlier target hikes linked to potential regulatory catalysts for mitapivat. Analyst Commentary Recent Street research on Agios Pharmaceuticals shows a mix of optimism around potential regulatory catalysts for mitapivat and caution around market sizing and competitive readthroughs, particularly following data points tied to Novo Nordisk.ナラティブの更新 • Apr 16
AGIO: Sickle Cell Regulatory Uncertainty Will Continue To Restrain Enthusiasm
Analysts have raised their price target on Agios Pharmaceuticals by $3 to a new fair value estimate of $28, citing recent target increases from major firms and growing attention on upcoming regulatory and clinical catalysts. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a mix of optimism around upcoming regulatory events and ongoing caution around execution risks, valuation and timing of potential catalysts.ナラティブの更新 • Apr 02
AGIO: Upcoming Regulatory Decisions In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have adjusted the fair value estimate for Agios Pharmaceuticals to $41.50 from $39.88, citing updated price targets and expectations tied to upcoming regulatory clarity on mitapivat, as well as broader support from recent research commentary. Analyst Commentary Recent Street research on Agios Pharmaceuticals centers on price target revisions, expectations around regulatory clarity for mitapivat in sickle cell disease, and the implications of the recent approval of Aqvesme.ナラティブの更新 • Mar 18
AGIO: Regulatory Clarity On Mitapivat In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have lifted the fair value estimate for Agios Pharmaceuticals by $1 to $39.88, citing higher price targets, expectations for regulatory clarity around mitapivat in sickle cell disease, and the recent approval of Aqvesme as key drivers of their updated outlook. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Agios Pharmaceuticals, with several price target revisions clustering in the US$25 to US$46 range and commentary centered on regulatory milestones, the impact of Aqvesme, and broader biotech sector conditions.ナラティブの更新 • Mar 04
AGIO: Thalassemia Decision And Recent Approval Will Drive Next Phase Upside
Analysts have nudged their intrinsic value estimate for Agios Pharmaceuticals higher to about $38.88 from $36.75, reflecting refreshed price targets in the $25 to $35 range and updated models following recent product approval and broader biotech sector tailwinds cited in recent research. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into the mid US$20s to mid US$30s, which aligns with the higher intrinsic value estimate around US$38.88 and indicates they see room for the shares to better reflect updated assumptions.ナラティブの更新 • Feb 18
AGIO: Sickle Cell Setback Will Continue To Restrain Enthusiasm Despite Thalassemia Approval
Analysts have lifted their fair value estimate for Agios Pharmaceuticals shares from $20 to $25, citing updated models that reflect recent drug approvals, ongoing FDA review milestones, and a series of higher Street price targets across the biotech sector. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a split view, with several bullish initiations and target hikes alongside more cautious revisions that highlight execution and growth risks around the company’s pipeline and commercial plans.ナラティブの更新 • Feb 03
AGIO: Thalassemia Decision And Aqvesme Approval Will Define Post RISE UP Upside
Narrative Update: Agios Pharmaceuticals (AGIO) Analysts have lifted Agios Pharmaceuticals' price targets into a US$25 to US$38 range, with recent tweaks to models reflecting the approval of Aqvesme, updated views on mitapivat and Pyrukynd, and a generally more constructive stance on U.S. biotech capital and deal activity. Analyst Commentary Recent Street research on Agios Pharmaceuticals shows a wide spread of views, with price targets clustered in the US$25 to US$38 range after earlier cuts from much higher levels.ナラティブの更新 • Jan 20
AGIO: Upcoming Thalassemia Decision Will Shape Post RISE UP Opportunity Narrative
Agios Pharmaceuticals’ fair value estimate edges up from US$36.00 to US$36.75 as analysts recalibrate models following recent target changes across the Street, reflecting updated views on Pyrukynd’s opportunity set, revised profit margin assumptions, and a higher future P/E multiple, despite some ongoing trial related uncertainties. Analyst Commentary Street research around Agios has become more divided, with some analysts leaning into the updated opportunity around Pyrukynd and other mitapivat indications, while others focus on execution risk and regulatory uncertainty following the RISE UP sickle cell disease data.ナラティブの更新 • Jan 06
AGIO: Upcoming FDA Thalassemia Decision Will Shape Post RISE UP Bullish Outlook
Analysts have lifted their aggregate fair value estimate for Agios Pharmaceuticals to $36.00 from $32.13, citing updated revenue and margin assumptions. This follows mixed views on the recent RISE UP data and new Street targets that range widely from US$20 to US$48, alongside Citi's fresh US$38 initiation and a near-term FDA catalyst watch.ナラティブの更新 • Dec 18
AGIO: Sickle Cell Setback Will Drive Cautious View Despite Upcoming FDA Decision
Analysts have cut their average price target on Agios Pharmaceuticals to $20 from $37, reflecting reduced expectations for mitapivat in sickle cell disease and more conservative long term revenue and expense assumptions, even as some still see upside around upcoming regulatory catalysts for Pyrukynd. Analyst Commentary Bearish analysts have responded to the RISE UP data by sharply recalibrating expectations for mitapivat in sickle cell disease, cutting price targets and, in some cases, ratings.ナラティブの更新 • Dec 04
AGIO: Upcoming FDA Decision Will Drive Bullish Outlook After Mixed Trial Data
Analysts have reduced their average price target on Agios Pharmaceuticals from about $42 to roughly $32 per share. This reflects higher perceived risk after mixed Phase 3 RISE UP data, tempered revenue and margin expectations, and a wider debate over the regulatory and commercial outlook for mitapivat and Pyrukynd across indications.ナラティブの更新 • Nov 20
AGIO: Regulatory Decisions Will Drive Outlook After Mixed Late-Stage Clinical Results
Agios Pharmaceuticals’ analyst price target has been reduced from approximately $47.50 to $42.33 per share. Analysts cite increased uncertainty for mitapivat in sickle cell disease following underwhelming Phase 3 trial results, as well as a more challenging regulatory and commercial pathway.ナラティブの更新 • Sep 05
FDA Approval And Global Partnerships Will Yield Mixed Prospects
Analysts modestly trimmed Agios Pharmaceuticals’ price target from $47.67 to $47.50, reflecting a brief FDA approval delay for Pyrukynd and cautious near-term modeling, while maintaining long-term conviction on the strength of clinical data and emerging commercial partnerships. Analyst Commentary Bullish analysts remain confident in FDA approval of Pyrukynd despite a three-month PDUFA delay due to the submission of a REMS for hepatocellular injury, which is viewed as a standard regulatory step and not due to new data requests.分析記事 • Feb 20
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem
We didn't see Agios Pharmaceuticals, Inc.'s ( NASDAQ:AGIO ) stock surge when it reported robust earnings recently. We...Seeking Alpha • Feb 14
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Summary Agios Pharmaceuticals' focus is on expanding Pyrukund's label to treat thalassemia and sickle cell disease, targeting multi-billion dollar markets. Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios' stock and could affect Pyrukund's approval and market adoption. Agios has a strong cash position of $1.5bn and potential blockbuster revenue opportunity, but safety issues warrant a cautious "Hold" rating. Monitoring progress and awaiting further clarity on safety issues and FDA decisions is advisable before making investment moves. Read the full article on Seeking Alpha
新しいナラティブ • Feb 09
Mitapivat May Launch In 2025 For Blood Disorders But Faces Regulatory And Competition Challenges
Mitapivat's launch in thalassemia and sickle cell markets promises revenue growth from new opportunities, leveraging positive Phase III data for adoption.Seeking Alpha • Jan 14
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
Summary Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their primary endpoints last year. The FDA has set a goal date of Sept. 7th 2025 to review the application and render a decision. Agios is well capitalized after $1.1 billion in milestones following the FDA's approval of vorasidenib, a drug divested when the company exited oncology in 2021. A third Phase III study named RISE UP has recruited patients to study PYRUKYND in sickle cell disease with results due in late-2025. Agios Pharma is rated a HOLD until further clarity on the commercialization of PYRUKYND occurs later this year. Read the full article on Seeking AlphaSeeking Alpha • Dec 03
Agios Pharmaceuticals: A Long Overdue Follow Up
Summary Today, we take a deeper look at commercial stage biopharma firm Agios Pharmaceuticals for the first time in more than two years. The shares have spiked up recently thanks in a large part to a huge cash infusion the company received in August. The company's one approved product on the market, PYRUKYND, has seen limited sales to date, but the compound is being evaluated to treat much larger potential indications. Read the full article on Seeking Alpha分析記事 • Sep 26
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 27
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Summary Agios’ Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 trials showing positive results for hemoglobin improvement. Expanding Pyrukynd’s label to include pediatric and thalassemia indications is crucial, with regulatory filings expected by 2025. Agios has a strong financial position, with a cash runway extending beyond 2027, bolstered by milestone payments. Despite risks, Agios’ mitapivat could become a blockbuster drug, making AGIO a compelling buy for biotech investors. Read the full article on Seeking Alpha分析記事 • Aug 04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) just released its latest second-quarter report and things are not looking...Seeking Alpha • Jun 12
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Summary Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for thalassemia and sickle cell disease, positioning itself for potential FDA approvals in 2025 and 2026. A $905 million upfront payment from Royalty Pharma is contingent on FDA approval of Vorasidenib by August 2024. Wells Fargo corroborates AGIO's potential by mentioning it as a potential acquisition target in biotech. Potential FDA approvals in 2025 and 2026 for Pyrukynd's new indications could significantly boost AGIO's revenue. I deem AGIO a strong buy. Read the full article on Seeking Alpha分析記事 • Jun 02
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...決済の安定と成長
配当データの取得
安定した配当: AGIOの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: AGIOの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Agios Pharmaceuticals 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (AGIO) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Biotechs) | 2.5% |
| アナリスト予想 (AGIO) (最長3年) | 0% |
注目すべき配当: AGIOは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: AGIOは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: AGIOの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: AGIOが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/10 06:03 |
| 終値 | 2026/06/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Agios Pharmaceuticals, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。28
| アナリスト | 機関 |
|---|---|
| Peter Lawson | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |